Lexicon Pharma (LXRX) Reports In-Line Q1 Loss of 4c/Share
Lexicon Pharma (NASDAQ: LXRX) reported Q1 EPS of ($0.04), in-line with the analyst estimate of ($0.04). Revenue for the quarter came in at $1.8 million versus the consensus estimate of $1.1 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
